Levodopa/Carbidopa

ABLi Therapeutics has completed an End of Phase 2 meeting with the FDA, securing support for innovative endpoints in upcoming Phase 3 trials for risvodetinib in Parkinson's disease.

Mitsubishi Tanabe Pharma America will present 11 studies at the American Academy of Neurology 2025 Annual Meeting, including research on investigational ND0612 for Parkinson's disease and RADICAVA formulations for ALS.

AbbVie's Vyalev, a 24-hour subcutaneous levodopa infusion, gained FDA approval for managing motor fluctuations in advanced Parkinson's, offering a novel therapeutic approach.

Mitsubishi Tanabe Pharma America (MTPA) presented data on ND0612, an investigational continuous subcutaneous infusion of levodopa/carbidopa, at the Parkinson Study Group (PSG) meeting.

One-year outcomes from the BouNDless open-label extension study confirm the long-term efficacy of ND0612 in managing motor fluctuations in Parkinson's disease.